In part 4 of the Oncology Value Coalition webinar, experts from City of Hope and Highmark discussed how the therapeutic pipeline has changed.
While genomic testing has changed the face of cancer care and ensure more informed decision making, designing precision medicine solutions cannot happen if patients lack access to testing, or if tests results are used incorrectly.
In the latest webinar from The American Journal of Managed Care®'s (AJMC®) Oncology Value Coalition, experts from City of Hope and Highmark highlighted the potential of genomic testing, the opportunities that exist through collaboration between academic centers and the private sector, and the barriers that some patients still face.
Joseph Alvarnas, MD, of City of Hope and editor-in-chief of AJMC®'s Evidence-Based Oncology™, moderated a discussion with:
In segment 4, panelists discuss how the therapeutic pipeline has changed.